Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191451 · ClinicalTrials.gov registry record · Phase 2
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00191451 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 150 participants.
The verdict
NCT00191451, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds. Whether the two or three drugs listed above when given in combination can help patients with metastatic breast cancer. How long the treatment will stop the growth of the cancer.
Interventions
- DRUG Carboplatin
- DRUG Gemcitabine
- DRUG Herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-04 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00191451
The ClinicalTrials.gov registry entry for NCT00191451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT00191451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00191451 about?
NCT00191451 is a clinical study titled "A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer". The purposes of this study are to determine the safety of gemcitabine and paraplatin either with or without trastuzumab Any side effects that might be associated with these compounds. Whether the two or three drugs listed above when given in combination can help patients with metastatic breast cance...
What is the current status of trial NCT00191451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-04. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00191451?
The interventions under investigation include: Carboplatin (DRUG), Gemcitabine (DRUG), Herceptin (DRUG).
Who is sponsoring clinical trial NCT00191451?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.